Articles related to PHARMACOTHERAPY

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine

The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.

“A fully oral, inexpensive NMDA-AMPA modulation strategy may offer a practical alternative for patients with the bipolar obsessive-compulsive disorder phenotype who respond poorly to conventional approaches.” — Ngo Cheung, MBBS

“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors

“We try to deescalate pharmacotherapy as soon as we can in children. How’s this going to affect puberty? How’s it going to affect growth? We don’t have those long-term data.”

Although not remarkably high, a 2.8% development of psychotic symptoms represents a nonnegligible figure and lends further meta-analytic support to the 2007 FDA change in the drug label for stimulants.